Cover Page
The handle
http://hdl.handle.net/1887/68231
holds various files of this Leiden University
dissertation.
Author: Engelberts, P.J.
Cover art Joost Bakker, scicomvisuals, Amsterdam, The Netherlands Production Joost Bakker, scicomvisuals, Amsterdam, The Netherlands Design & Dtp De vliegende kiep,
Amsterdam, The Netherlands Printed by
Ipskamp Printing, Enschede ISBN/EAN: 978 94 028 1260 2 Proefschrift Universiteit Leiden, Faculteit Geneeskunde
© 2018, Petrus Johannes Engelberts, The Netherlands
proefschrift
Ter verkrijging van de graad van doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens het besluit van het College voor Promoties te verdedigen op
donderdag 10 Januari 2019 klokke 16:15 uur
door
Petrus Johannes Engelberts
Geboren op 17 September 1975,te Utrecht
Promotor
Prof. Dr. P.W.H.I. Parren Co-promotor Dr. E.C.W. Breij Promotiecommissie Prof. Dr. M. de Haas Prof. Dr. J.J.C. Neefjes Dr. T. van Hall
Table of Contents
Chapter 1 General outline and aim of the thesis 9
Chapter 2 The evolution of immunotherapy: lessons learned from targeting CD20 19
Chapter 3 A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: proof of principle with rituximab and ofatumumab 77
Chapter 4 Type I CD20 antibodies recruit the B-cell receptor for complement-dependent lysis of malignant B cells 99
Chapter 5 Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic CD20 antibodies: implications for combination therapy 125 Chapter 6 DuoBody®-CD3xCD20, an Fc-silenced whole IgG
T cell retargeting bispecific antibody, displays unique capacity to induce T-cell mediated kill of malignant B cells, and provides opportunities for subcutaneous dosing 147
Chapter 7 General discussion of the thesis 187
Summary 217
Samenvatting in het Nederlands 219
Dankwoord 222
Publications 224
Abbreviations 226
